Takeda

Eisai, Takeda and GARDP hunt for new antibiotics
Eisai, Takeda and GARDP hunt for new antibiotics
Pharmaforum
Eisai
Takeda
GARDP
antibiotics
R&D
Flag link:
Multiple Myeloma Research Foundation Bets on Adaptive Platform Clinical Trial Design
Multiple Myeloma Research Foundation Bets on Adaptive Platform Clinical Trial Design
Xtalks
clinical trials
Multiple Myeloma
adaptive trial design
AbbVie
Celgene
Eli Lilly
Genentech
Janssen
Takeda
Flag link:
What do Martin Shkreli, Gilead and Takeda have in common? They all figure prominently in the new top-20 list of the world’s most expensive drugs
What do Martin Shkreli, Gilead and Takeda have in common? They all figure prominently in the new top-20 list of the world’s most expensive drugs
Endpoints
Takeda
Gilead Sciences
Martin Shkreli
drug pricing
Flag link:
A last-ditch effort to derail Takeda’s $62B Shire buyout goes down in flames
A last-ditch effort to derail Takeda’s $62B Shire buyout goes down in flames
Endpoints
Takeda
Shire
M&A
Flag link:
Takeda Acquisition Of Shire May Bode Well For R&D Staff
Takeda Acquisition Of Shire May Bode Well For R&D Staff
Forbes
Shire
Takeda
R&D
M&A
Flag link:
Takeda ready to dismiss assets for a total $10bn
Takeda ready to dismiss assets for a total $10bn
GoinPharma
Takeda
Shire
M&A
Flag link:
ASH: Takeda maintenance data sets up Ninlaro for new myeloma nod
ASH: Takeda maintenance data sets up Ninlaro for new myeloma nod
Fierce Pharma
ASH2018
Takeda
Ninlaro
Multiple Myeloma
Flag link:
Takeda could rack up $10B in selloffs after controversial Shire buyout: report
Takeda could rack up $10B in selloffs after controversial Shire buyout: report
Fierce Pharma
Takeda
Shire
M&A
shareholders
Flag link:
A Small Group of Pharma Companies Is Making the Bulk of Medicines Necessary for Developing Countries
A Small Group of Pharma Companies Is Making the Bulk of Medicines Necessary for Developing Countries
BioSpace
GSK
JNJ
Novartis
Merck KGaA
Sanofi
Takeda
developing countries
Flag link:
Takeda clears final regulatory hurdle to completing its $62B Shire deal. Now only one obstacle remains
Takeda clears final regulatory hurdle to completing its $62B Shire deal. Now only one obstacle remains
Endpoints
Takeda
shareholders
Japan
M&A
Shire
Europe
Flag link:
Drug Approvals for the 2 Most Common Types of Cancer in the Last 2 Years
Drug Approvals for the 2 Most Common Types of Cancer in the Last 2 Years
BioSpace
cancer
breast cancer
lung cancer
drug approvals
AstraZeneca
Takeda
Ariad Pharmaceuticals
Merck
Pfizer
Novartis
Boehringer Ingelheim
Bristol-Myers Squibb
Eli Lilly
Puma Biotechnology
Mylan
Genentech
Flag link:
Takeda investors mount last-minute effort to stymie Shire deal: FT
Takeda investors mount last-minute effort to stymie Shire deal: FT
Fierce Pharma
Takeda
Shire
shareholders
M&A
Flag link:
With the $62B Shire buyout on track, Takeda plans to debut the newly merged company at JPMorgan
With the $62B Shire buyout on track, Takeda plans to debut the newly merged company at JPMorgan
Endpoints
Takeda
Shire
M&A
Christophe Weber
Flag link:
Exclusive: Takeda to win EU approval for US$62 billion Shire deal - sources
Exclusive: Takeda to win EU approval for US$62 billion Shire deal - sources
Channel News Asia
Takeda
Shire
M&A
Europe
Flag link:
Takeda CEO confident about Shire merger
Takeda CEO confident about Shire merger
Pharmaforum
Takeda
Shire
M&A
shareholders
Pharma CEOs
Christophe Weber
Flag link:
Positive quarter from Takeda, waiting for completion of Shire deal
Positive quarter from Takeda, waiting for completion of Shire deal
GoinPharma
Takeda
Shire
M&A
earnings
Flag link:
Takeda considering sale of OTC business in Europe ($11bn)
Takeda considering sale of OTC business in Europe ($11bn)
Bloomberg
Takeda
Shire
M&A
OTC
Flag link:
Takeda is ready to auction off a PhIII favorite at Shire to clear the last hurdles to a $62B buyout
Takeda is ready to auction off a PhIII favorite at Shire to clear the last hurdles to a $62B buyout
Enpoints
Takeda
Shire
inflammatory bowel disease
IBD
ulcerative colitis
Crohn's Disease
M&A
SHP647
Flag link:
Ready to Roll! Ten Q3 Biotech Earnings Reports to Watch Next Week
Ready to Roll! Ten Q3 Biotech Earnings Reports to Watch Next Week
BioSpace
BrainStorm Cell Therapeutics
Allergan
Pfizer
Clovis Oncology
Acorda Therapeutics
Takeda
Agios Pharmaceuticals
Shire
Teva Pharmaceutical
AbbVie
Flag link:
Microbiome Biotech Enterome and Takeda sign Crohn's Deal Worth Up To $600 Million+
Microbiome Biotech Enterome and Takeda sign Crohn's Deal Worth Up To $600 Million+
CP Wire
Enterome
Takeda
Crohn's Disease
EB8018
Flag link:

Pages